CAJ | 학술논문

目的：探讨曲妥珠单抗辅助化疗对HER-2过度表达老年性乳腺癌的安全性及临床疗效。方法：选取我院32例HER-2过表达的老年乳腺癌患者,均采用乳腺癌根治术联合曲妥珠单抗辅助治疗,观察其临床疗效及曲妥珠单抗辅助治疗安全性。结果：26例曲妥珠单抗治疗超过1年(81.3%),平均曲妥珠单抗维持治疗时间9.5个月(2～12个月),3例由于毒副作用停止曲妥珠单抗治疗。本组患者生存率75.0%(24/32),死亡率25.0%(8/32),其中肿瘤死亡9.4%(3/32),非肿瘤死亡18.7%(6/32)。治疗后未复发率68.7%(22/32),2例出现远处转移。全组无治疗性死亡,患者不良反应以食欲不振、恶心呕吐、脱发及色素沉着为最常见,患者大都可耐受。结论：曲妥珠单抗作为辅助治疗能提高HER-2高表达的老年乳腺癌患者的治疗有效率,延长复发时间,也延长了患者生存时间,且不良反应较易耐受。
목적：탐토곡타주단항보조화료대HER-2과도표체노년성유선암적안전성급림상료효。방법：선취아원32례HER-2과표체적노년유선암환자,균채용유선암근치술연합곡타주단항보조치료,관찰기림상료효급곡타주단항보조치료안전성。결과：26례곡타주단항치료초과1년(81.3%),평균곡타주단항유지치료시간9.5개월(2～12개월),3례유우독부작용정지곡타주단항치료。본조환자생존솔75.0%(24/32),사망솔25.0%(8/32),기중종류사망9.4%(3/32),비종류사망18.7%(6/32)。치료후미복발솔68.7%(22/32),2례출현원처전이。전조무치료성사망,환자불량반응이식욕불진、악심구토、탈발급색소침착위최상견,환자대도가내수。결론：곡타주단항작위보조치료능제고HER-2고표체적노년유선암환자적치료유효솔,연장복발시간,야연장료환자생존시간,차불량반응교역내수。
Objective: To discuss Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients. Methods:Choose 32 elderly patients of breast cancer with HER-2-overexpressing, all treated by curative surgery and adjuvant trastuzumab, and observe its clinical curative effect and security. Results:A total of 26 patients (81.3%) completed 1-year trastuzumab treatment. The median treatment duration was 9.5 months (range 2~12 months). Three discontinued or interrupted treatment after experiencing toxicity. The survival rate was 75.0%(24/32), the death rate 25.0%(8/32), in which cancer death was 9.4%(3/32), the cancer death 18.7%(6/32). treatment without recurrence rate was 68.7%(22/32), 2 cases appeared distant metastases. No case dead in the progress of treatment, and the most common adverse reactions were loss of appetite, nausea, vomiting, hair loss and pigmentation, which most patients could tolerate. Conclusion:Trastuzumab can improve the rate of treatment HER-2-overexpressing elderly breast cancer patients, extended the time of relapse and survival time, adverse reactions to tolerate more easily.